CXW Q1 2026 Earnings Call Summary | Stock Taper
Logo
Pricing Sign Up Log In
CXW

CXW — CoreCivic, Inc.

NYSE

Q1 2026 Earnings Call Summary

May 7, 2026

CoreCivic, Inc. (CXW) Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

  • GAAP EPS: $0.38 per share; Adjusted EPS: $0.40 (up 74% YoY from $0.23).
  • Normalized FFO per share: $0.65 (up 44% YoY from $0.45).
  • Adjusted EBITDA: $110.1 million (up 36% YoY from $81 million).
  • Occupancy Rate: 79.6%, an increase of 2.6 percentage points YoY.
  • Average Daily Population: 57,243 individuals, up from 51,429 YoY.
  • Revenue from Federal Partners: Increased 48% YoY, primarily from ICE, which accounted for 58% of total revenue.
  • Share Repurchases: 2.3 million shares repurchased at $44.7 million during Q1.

2. Strategic Updates and Business Highlights

  • CoreCivic activated five idle facilities to meet increased demand, particularly from ICE.
  • The acquisition of Clinical Solutions Pharmacy (CSP) for $148 million is expected to diversify revenue and address the growing medical needs of correctional populations.
  • The company continues to maintain five idle facilities with approximately 7,000 beds available for future demand.
  • CoreCivic is focused on operational excellence and has seen strong demand from state partners, with a 3.6% revenue increase from state contracts.

3. Forward Guidance and Outlook

  • 2026 Guidance:
    • Diluted EPS: $1.51 to $1.61; Adjusted Diluted EPS: $1.53 to $1.63.
    • FFO per share: $2.58 to $2.68; Normalized FFO per share: $2.60 to $2.70.
    • Adjusted EBITDA: $453.8 million to $461.8 million.
  • The guidance reflects a temporary decline in ICE populations expected in Q2, with a forecasted recovery in the second half of the year.
  • CSP is projected to generate $215 million to $230 million in revenue for 2026, contributing $0.03 to $0.05 per share.

4. Bad News, Challenges, or Points of Concern

  • Declining ICE Populations: After peaking in January, ICE populations decreased by approximately 10,500 by early April, attributed to a government shutdown and redeployment of ICE agents.
  • Potential Risks: The company faces uncertainty regarding future ICE population growth and the impact of government funding on contract awards.
  • Market Competition: ICE's interest in converting warehouses into detention facilities may pose competitive pressures on CoreCivic's traditional facility model.

5. Notable Q&A Insights

  • Management expressed confidence that the decline in ICE populations is temporary and linked to specific events rather than a long-term trend.
  • Discussions about potential asset sales to ICE highlighted the complexity of valuation and operational responsibilities.
  • The company is actively pursuing new state contracts but noted the unpredictability of state procurement timelines.
  • CSP's acquisition is seen as a strategic move to leverage synergies and expand market reach, with a significant growth potential in the correctional pharmacy space.

In summary, CoreCivic reported strong financial results in Q1 2026, driven by increased occupancy and federal revenues, while also navigating challenges related to ICE population fluctuations and competitive pressures. The strategic acquisition of CSP is expected to enhance growth prospects, although management remains cautious about future population trends and government funding dynamics.

← Q4 2025